
Satellos Bioscience Inc. (NASDAQ:MSLE – Free Report) – HC Wainwright lowered their FY2026 EPS estimates for shares of Satellos Bioscience in a note issued to investors on Friday, November 13th. HC Wainwright analyst A. He now forecasts that the company will post earnings per share of ($2.01) for the year, down from their previous forecast of ($1.92). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Satellos Bioscience’s current full-year earnings is ($1.90) per share. HC Wainwright also issued estimates for Satellos Bioscience’s Q4 2026 earnings at ($0.39) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.45) EPS, Q3 2027 earnings at ($0.47) EPS, Q4 2027 earnings at ($0.49) EPS, FY2027 earnings at ($1.85) EPS, FY2028 earnings at ($1.84) EPS, FY2029 earnings at ($0.86) EPS and FY2030 earnings at $0.87 EPS.
Satellos Bioscience (NASDAQ:MSLE – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09).
View Our Latest Stock Report on MSLE
Satellos Bioscience Stock Down 4.2%
MSLE stock opened at $5.94 on Tuesday. The company has a fifty day moving average price of $7.58 and a 200-day moving average price of $8.16. Satellos Bioscience has a 52-week low of $5.44 and a 52-week high of $13.39.
Hedge Funds Weigh In On Satellos Bioscience
A hedge fund recently raised its position in Satellos Bioscience stock. AWM Investment Company Inc. boosted its position in Satellos Bioscience Inc. (NASDAQ:MSLE – Free Report) by 41.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 305,000 shares of the company’s stock after buying an additional 90,000 shares during the period. AWM Investment Company Inc. owned approximately 1.46% of Satellos Bioscience worth $2,338,000 at the end of the most recent quarter.
Key Headlines Impacting Satellos Bioscience
Here are a few of the latest headlines about MSLE:
- Positive Sentiment: HC Wainwright raised its estimates for Q4 2026 and each quarter of 2027, as well as full-year 2027–2030. Its forecast now sees Satellos reaching positive EPS of $0.87 in 2030, up from $0.86. The firm reiterated its Buy rating and $18 price target. MarketBeat coverage
- Negative Sentiment: HC Wainwright lowered its FY2026 EPS estimate to a loss of $2.01 per share from a loss of $1.92, implying greater near-term losses. The company is still forecast to post losses through 2029 despite the improved longer-term estimates. MarketBeat coverage
Satellos Bioscience Company Profile
Satellos Bioscience is a biotechnology company developing treatments intended to improve the body’s ability to repair and regenerate muscle. Its research focuses on muscle stem cells and the cellular processes that guide their function. The company’s lead program, SAT-3247, is an investigational oral small-molecule therapy being developed for Duchenne muscular dystrophy. Satellos is studying whether its approach can restore muscle stem-cell activity and support muscle regeneration; the candidate remains in development and is not an approved treatment.
Read More
- Five stocks we like better than Satellos Bioscience
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Satellos Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satellos Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
